D. Boral Capital reiterated their buy rating on shares of Medicus Pharma (NASDAQ:MDCX - Free Report) in a research report report published on Monday,Benzinga reports. They currently have a $14.00 price objective on the stock.
A number of other equities research analysts have also recently issued reports on the stock. Brookline Capital Management upgraded shares of Medicus Pharma to a "strong-buy" rating in a research report on Monday, December 23rd. D Boral Capital raised shares of Medicus Pharma to a "strong-buy" rating in a report on Monday, April 14th.
Read Our Latest Analysis on MDCX
Medicus Pharma Stock Down 0.3 %
MDCX traded down $0.01 during midday trading on Monday, reaching $3.95. 81,510 shares of the company's stock were exchanged, compared to its average volume of 51,653. The company's 50-day moving average is $3.58. Medicus Pharma has a one year low of $1.80 and a one year high of $6.00.
Medicus Pharma (NASDAQ:MDCX - Get Free Report) last posted its earnings results on Friday, March 28th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.14. Equities research analysts expect that Medicus Pharma will post -1.14 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Medicus Pharma stock. Interchange Capital Partners LLC acquired a new stake in Medicus Pharma Ltd. (NASDAQ:MDCX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 1,457,165 shares of the company's stock, valued at approximately $3,628,000. Medicus Pharma makes up approximately 1.3% of Interchange Capital Partners LLC's portfolio, making the stock its 15th biggest holding. Interchange Capital Partners LLC owned about 13.43% of Medicus Pharma as of its most recent filing with the SEC.
Medicus Pharma Company Profile
(
Get Free Report)
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
See Also
Before you consider Medicus Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicus Pharma wasn't on the list.
While Medicus Pharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
